This list includes the therapeutic categories
in order of their codes. This allows you to
see the hierarchy involved in the classification.
| G |
GENITOURINARY (including sex hormones) |
| G1C |
FERTILITY ENHANCER
Products for the treatment of male or female infertility. Products for female infertility include gonadotrophin derivatives such as recombinant HCG, LH and FSH, erythroid differentiation factors and prostaglandin E2. Agents for male infertility include melatonin antagonists, gonadorelin analogues and recombinant somatropin (human growth hormone).
|
| G2A |
LABOUR INDUCER
Drugs acting on the myometrium are classified as oxytocics (uterus-contracting drugs) or as tocolytics (uterine relaxants, see G2B). New oxytocic agents include preparations of dinoprostone and the peptide hormone, relaxin. |
| G2B |
LABOUR INHIBITOR
Drugs acting on the myometrium are classified as tocolytics (uterine relaxants) or as oxytocics (uterus-contracting drugs, see G2A). New tocolytics include oxytocin antagonists, antimuscarinic agents and calcium channel blockers. |
| G3A |
MENSTRUATION DISORDERS
Products in development for the treatment of amenorrhoea, dysmenorrhoea, endometriosis and abnormal uterine bleeding which includes hypermenorrhoeas, menorrhagia, polymenorrhoea, metrorrhagia and postmenopausal bleeding include LHRH (gonadorelin) analogues, progestogens and synthetic steroids. |
| G3B |
MENOPAUSAL DISORDERS
Products for the prevention and treatment of menopausal symptoms include hormone replacement therapies, such as estrogen alone, progesterone alone, and estrogen and progesterone combined. |
| G3C |
FEMALE CONTRACEPTIVE
Agents that are used as female contraceptive products including combined compounds that contain ethinylestradiol and norethisterone, progestogen-only agents, contraceptive vaccines, antiestrogens and gonadorelin (LHRH) antagonists. |
| G3D |
ABORTIFACIENT
Abortifacients in development for the premature expulsion from the uterus of the embryo or foetus include prostaglandin analogues. |
| G3E |
FEMALE SEXUAL DYSFUNCTION
Products involved in the treatment of female sexual dysfunction, which includes the following disorders: female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), anorgasmia and dyspareunia. |
| G4Z |
UROLOGICAL
Products for the treatment of renal insufficiency (eg atrial natriuretic factor analogues), dysuria (eg a -adrenoceptor antagonists), enuresis (eg desmopressin formulations), incontinence (eg m opioid receptor agonists), urinary calculi (eg urease inhibitors) and for urological (non-reproductive/gonadal) applications that cannot be classified elsewhere. |
| G5A |
PROSTATE DISORDERS
Products that are used in the treatment of benign prostatic hyperplasia (BPH), including 5a -reductase inhibitors, antiandrogens and a 1-adrenoceptor antagonists. |
| G5B |
MALE SEXUAL DYSFUNCTION
Products that are involved in the treatment of male sexual dysfunction including a -adrenoceptor antagonists and androgens. |
| G5C |
MALE CONTRACEPTIVE
Agents in development as male contraceptives include recombinant forms of bovine, porcine and human inhibin and gonadorelin agonists which may be used with supplementary androgens. |
| G6Z |
REPRODUCTIVE/GONADAL, GENERAL
Products that are being developed for the treatment of reproductive/gonadal disorders, which are not easily classified elsewhere. (For urological disorders, see G4Z). Products for the treatment of hypogonadism (eg testosterone formulations), Turner's syndrome (eg androgen agonists), and precocious puberty (eg gonadorelin analogues). |
Dialog1
Support Home
View the PDF version of this document